
FDMT Stock Forecast & Price Target
FDMT Analyst Ratings
Bulls say
4D Molecular Therapeutics is demonstrating strong progress in their clinical trials for 4D-150, supported by an experienced leadership team and a competitive pipeline in larger indications. At $26 per share, their current valuation is based on probability-adjusted modeling, which projects $484.6 million in peak sales for wet AMD and $123.2 million for DME by 2034. The company may face challenges in manufacturing and future financing, but the potential for a significant market share in these indications makes 4D Molecular Therapeutics an attractive investment.
Bears say
4D Molecular Therapeutics is a biotechnology company with a focus on developing gene therapies for eye and lung diseases. However, the negative outlook on the company's stock is based on concerns about the potential for competition from other emerging therapies, the risk of setbacks in clinical trials, and the possibility of delays in the development and commercialization of their products due to the complexity of manufacturing gene therapies. Additionally, there are uncertainties surrounding the potential market size for their products and their ability to compete with established treatments in the market. The current estimated peak sales for one of their key products, 4D-710 for cystic fibrosis, is $527.6mm in 2034E. Given these factors, there is a high level of risk associated with investing in the company, which warrants a negative outlook on the stock.
This aggregate rating is based on analysts' research of 4D Molecular Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
FDMT Analyst Forecast & Price Prediction
Start investing in FDMT
Order type
Buy in
Order amount
Est. shares
0 shares